Journal of Shanghai Jiao Tong University (Medical Science) >
Effect of intragastric treatment of sodium cromoglycate on dextran sulfate sodium-induced ulcerative colitis in BALB/c mice
Received date: 2022-05-15
Accepted date: 2022-09-13
Online published: 2022-12-02
Supported by
National Natural Science Foundation of China(81871267);Science and Technology Commission of Shanghai Municipality of Scientific and Technological Research(19441904300)
Objective ·To explore the role of mast cell membrane stabilizer sodium cromoglycate (Crom) in the modeling of ulcerative colitis (UC) in mice. Methods ·Mice were divided into 3 groups, i.e.control group (n=5), dextran sulfate sodium (DSS) group (n=5) and DSS+Crom group (n=5). Mice in the control group drank water for 7 d, and mice in the DSS group drank 3% DSS for 7 d to establish UC model. Meanwhile, mice in the DSS+Crom group were treated with Crom since the 3rd day during the establishment of UC. The changes of body mass and disease activity index (DAI) scores among the three groups were compared. Hematoxylin-eosin staining (H-E staining) and toluidine blue staining were used to observe the histopathology injury and the number of mast cells in colon tissues. Flow cytometry was used to detect the immune cell infiltration of spleen. Differences among the three groups were compared by using one-way ANOVA. Least significant difference (LSD) was used to further compare the differences between each two groups. Results ·Compared with the control group, the mice in the DSS group had severe hematochezia and intestinal barrier injury, the body weight of the mice in the DSS group decreased significantly (P=0.005), the DAI score increased significantly (P=0.001), the colon length shortened significantly (P=0.003), and toluidine blue staining showed that the number of mast cells in the intestine increased (P=0.000). Moreover, compared with the DSS group, the blood in the stool of the mice in the DSS+Crom group decreased, and the colon length increased (P=0.013); the intestinal pathology showed that the inflammation was improved, and the number of mast cells was reduced (P=0.000). Conclusion ·Stabilizing mast cells with sodium cromoglycate could effectively reduce colon inflammation of mice in UC, which indirectly indicates that mast cells participate in the pathogenesis of UC.
Yiqin GE , Yuji HUANG , Weize LI , Yanning LI , Li LI . Effect of intragastric treatment of sodium cromoglycate on dextran sulfate sodium-induced ulcerative colitis in BALB/c mice[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2022 , 42(10) : 1375 -1382 . DOI: 10.3969/j.issn.1674-8115.2022.10.002
1 | WINDSOR J W, KAPLAN G G. Evolving epidemiology of IBD[J]. Curr Gastroenterol Rep, 2019, 21(8): 40. |
2 | 金怀亮, 张建华. 1990—2017年中国人群炎性肠病发病率及患病率变化趋势[J]. 湖北医药学院学报, 2021, 40(2): 187-189, 196. |
2 | JIN H L, ZHANG J H. Trend of incidence and prevalence of inflammatory bowel disease in Chinese from 1990 to 2017[J].J Hubei Univ Med, 2021, 40(2): 187-189, 196. |
3 | KAPLAN G G. The global burden of IBD: from 2015 to 2025[J]. Nat Rev Gastroenterol Hepatol, 2015, 12(12): 720-727. |
4 | LEI Y, CHEN Y, LIN Z Y, et al. Comprehensive analysis of key biomarkers, immune infiltration and potential therapeutic agents for ulcerative colitis[J]. Life Sci, 2020, 260: 118437. |
5 | BISCHOFF S C. Mast cells in gastrointestinal disorders[J]. Eur J Pharmacol, 2016, 778: 139-145. |
6 | HAMILTON M J, SINNAMON M J, LYNG G D, et al. Essential role for mast cell tryptase in acute experimental colitis[J]. Proc Natl Acad Sci USA, 2011, 108(1): 290-295. |
7 | HANSBRO P M, HAMILTON M J, FRICKER M, et al. Importance of mast cell Prss31/transmembrane tryptase/tryptase-γ in lung function and experimental chronic obstructive pulmonary disease and colitis[J]. J Biol Chem, 2014, 289(26): 18214-18227. |
8 | MINUTELLO K, GUPTA V. Cromolyn Sodium [M]. Treasure Island (FL): StatPearls Publshing, 2022. |
9 | 孙洁, 袁勇, 辛露, 等. 复方色甘酸钠鼻喷雾剂治疗变应性鼻炎的疗效观察[J]. 中国耳鼻咽喉颅底外科杂志, 2006, 12(6): 432-435. |
9 | SUN J, YUAN Y, XIN L, et al. Study on therapeutic effect of complex prescription cromolyn sodium nasal spray in the treatment of allergic rhinitis[J]. Chin J Otorhinolaryngol Skull Base Surg, 2006, 12(6): 432-435. |
10 | STRAUSS R A. Nasal cromolyn in the treatment of rhinitis[J]. J Allergy Clin Immunol Pract, 2020, 8(8): 2841-2842. |
11 | 张远超, 张亦田. 依美斯汀联合色甘酸钠治疗过敏性结膜炎的疗效分析[J]. 中国现代药物应用, 2017, 11(19): 134-135. |
11 | ZHANG Y C, ZHANG Y T. Efficacy of emedastine and sodium cromoglycate in allergic conjunctivitis[J]. Chin J Mod Drug Appl, 2017, 11(19): 134-135. |
12 | 李慧萍. 地塞米松联合色甘酸钠治疗过敏性结膜炎的临床观察[J]. 大家健康(中旬版), 2018, 12(5): 42-43. |
12 | LI H P. Clinical observation of dexamethasone combined with sodium cromoglycate in the treatment of allergic conjunctivitis[J]. For all health, 2018, 12(5): 42-43. |
13 | 郑秀丽, 聂淑英, 马圆圆, 等. 易激胶囊联合色甘酸钠治疗腹泻型肠易激综合征45例临床观察[J]. 河北中医, 2013, 35(4): 578-580. |
13 | ZHENG X L, NIE S Y, MA Y Y, et al. Treatment of diarrhea-predominant irritable bowel syndrome by combined therapy of Yiji capsule and sodium cromoglycate[J]. Hebei J TCM, 2013, 35(4): 578-580. |
14 | 赵亚妮, 李瑶, 张妍, 等. 葡聚糖硫酸钠不同给药方式建立小鼠溃疡性结肠炎模型[J]. 实验动物与比较医学, 2021, 41(1): 33-39. |
14 | ZHAO Y Z, LI Y, ZHANG Y, et al. Establishment of ulcerative colitis model in mice by different drug delivery methods of dextran sodium sulfate[J]. Lab Anim Comp Med, 2021, 41(1): 33-39. |
15 | CHASSAING B, AITKEN J D, MALLESHAPPA M, et al. Dextran sulfate sodium (DSS)-induced colitis in mice[J]. Curr Protoc Immunol, 2014, 104(1): 15.25.1-15.25.14. |
16 | OKAYASU I, HATAKEYAMA S, YAMADA M, et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice[J]. Gastroenterology, 1990, 98(3): 694-702. |
17 | EKSTR?M G M. Oxazolone-induced colitis in rats: effects of budesonide, cyclosporin A, and 5-aminosalicylic acid[J]. Scand J Gastroenterol, 1998, 33(2): 174-179. |
18 | DA SILVA E Z M, JAMUR M C, OLIVER C. Mast cell function: a new vision of an old cell[J]. J Histochem Cytochem, 2014, 62(10): 698-738. |
19 | CHURCH M K, KOLKHIR P, METZ M, et al. The role and relevance of mast cells in urticaria[J]. Immunol Rev, 2018, 282(1): 232-247. |
20 | NEUMANN D, SEIFERT R. The therapeutic potential of histamine receptor ligands in inflammatory bowel disease[J]. Biochem Pharmacol, 2014, 91(1): 12-17. |
21 | BOECKXSTAENS G. Mast cells and inflammatory bowel disease[J]. Curr Opin Pharmacol, 2015, 25: 45-49. |
22 | NOLTE H, SPJELDNAES N, KRUSE A, et al. Histamine release from gut mast cells from patients with inflammatory bowel diseases[J]. Gut, 1990, 31(7): 791-794. |
23 | PLANELL N, LOZANO J J, MORA-BUCH R, et al. Transcriptional analysis of the intestinal mucosa of patients with ulcerative colitis in remission reveals lasting epithelial cell alterations[J]. Gut, 2013, 62(7): 967-976. |
24 | JACOB C, YANG P C, DARMOUL D, et al. Mast cell tryptase controls paracellular permeability of the intestine. Role of protease-activated receptor 2 and β-arrestins[J]. J Biol Chem, 2005, 280(36): 31936-31948. |
25 | SKAPER S D, FACCI L, ZUSSO M, et al. Neuroinflammation, mast cells, and Glia: dangerous liaisons[J]. Neuroscientist, 2017, 23(5): 478-498. |
26 | CARDAMONE C, PARENTE R, FEO G D, et al. Mast cells as effector cells of innate immunity and regulators of adaptive immunity[J]. Immunol Lett, 2016, 178: 10-14. |
27 | METCALFE D D, BARAM D, MEKORI Y A. Mast cells[J]. Physiol Rev, 1997, 77(4): 1033-1079. |
28 | ZHANG T, FINN D F, BARLOW J W, et al. Mast cell stabilisers[J]. Eur J Pharmacol, 2016, 778: 158-168. |
/
〈 |
|
〉 |